AC Immune SA (ACIU) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AC Immune SA (ACIU) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 35.0% versus a loss of 65.2%. Over five years, DRUG leads with a -7.3% price change compared with -62.3% for ACIU. Bright Minds Biosciences is the larger company by market cap ($201.2 million vs $193.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | DRUG |
|---|---|---|
| Share price | $1.95 | $20.40 |
| Market cap | $193.88M | $201.23M |
| 1-day change | -8.45% | -1.45% |
| YTD return | -37.90% | -73.86% |
| 1-year return | -35.00% | -65.18% |
| 5-year return | -62.28% | -7.27% |
| Forward P/E | 2.84 | — |
| EPS (TTM) | $-0.44 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $123.75 |
| 52-week low | $1.93 | $17.40 |
| Distance from 52-week high | -50.00% | -83.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +331.28% | +426.18% |
| Average volume | 198.81K | 173.24K |
| Shares outstanding | 99.43M | 9.86M |
| Employees | 90 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed DRUG by 30.2 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
ACIU vs DRUG FAQ
Which is bigger, AC Immune SA or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $201.23M compared with $193.88M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or DRUG?
ACIU returned -35.00% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.